Caspofungin
- Generic Name
- Caspofungin
- Brand Names
- Cancidas, Cancidas (previously Caspofungin MSD)
- Drug Type
- Small Molecule
- Chemical Formula
- C52H88N10O15
- CAS Number
- 162808-62-0
- Unique Ingredient Identifier
- F0XDI6ZL63
- Background
Caspofungin (brand name Cancidas worldwide) is an antifungal drug and the first member of a new drug class called the echinocandins, as coined by Merck & Co., Inc. It is typically administered intravenously. It shows activity against infections with Aspergillus and Candida, and works by inhibiting β(1,3)-D-Glucan of the fungal cell wall.
- Indication
For the treatment of esophageal candidiasis and invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
- Associated Conditions
- Abscess, Intra-Abdominal, Candidemia, Esophageal Candidiasis, Fungal Infections, Invasive Aspergillosis, Oropharyngeal Candidiasis, Peritonitis, Pleural space infections
MK0991 in Combination With Standard Antifungal Agent(s) for the Treatment of Salvage Invasive Aspergillosis (0991-037)
- Conditions
- Aspergillosis
- First Posted Date
- 2004-02-06
- Last Posted Date
- 2015-01-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 55
- Registration Number
- NCT00076869
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment
- Conditions
- Cancer
- First Posted Date
- 2003-09-04
- Last Posted Date
- 2013-01-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Registration Number
- NCT00008359
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Caspofungin Acetate in Treating Children With Fever and Neutropenia
- Conditions
- Fever, Sweats, and Hot FlashesInfectionKidney CancerLeukemiaLymphomaNeuroblastomaNeutropeniaSarcoma
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-19
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT00020527
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Lombardi Cancer Center, Washington, District of Columbia, United States
🇺🇸Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.